Toctino (alitretinoin) / Basilea - LARVOL DELTA

Comparison of Systemic and Topical Retinoids and the Association of Inflammatory Bowel Disease in Ichthyosis Patients: A Population-Based Cohort Study (AAD 2026) - "Patients with acquired ichthyosis, congenital ichthyosis , or ichthyosis vulgaris treated with systemic retinoids such as alitretinoin, isotretinoin, etretinate, and acitretin (n=449) were identified using validated ICD-10 codes. A comparator cohort treated with topical retinoids such as adapalene, tazarotene, bexarotene, alitretinoin, and tretinoin (n=449) was established... These findings indicate that the protective association is specific to systemic retinoid therapy and highlights the importance of treatment selection in patients with ichthyosis who have comorbid or potential IBD. Future studies should further explore the role of systemic retinoids as potential disease-modifying agents for IBD and other inflammatory conditions in ichthyosis patients."

Clinical • Atopic Dermatitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Vitiligo

A Comparison of the Protective effects of Systemic vs Oral Retinoids on Non Melanoma Skin Cancers in Acne Patients: A Retrospective Cohort Study (AAD 2026) - "Two matched cohorts were created: systemic retinoids (alitretinoin, isotretinoin, etretinate, acitretin; n=34,851) and topical retinoids (adapalene, tazarotene, bexarotene, tretinoin; n=34,851). Patients with known NMSC risk factors (chemical exposures, HPV, or use of BRAF inhibitors, cyclosporine, voriconazole, hydrochlorothiazide) were excluded... The enhanced protective effect of systemic retinoids may reflect their deeper influence on keratinocyte turnover and skin cell regeneration compared to topical formulations. Further studies are warranted to clarify the relative efficacy of individual agents and optimize retinoid prophylaxis in high-risk patients."

Retrospective data • Acne Vulgaris • Basal Cell Carcinoma • Genetic Disorders • Kaposi Sarcoma • Non-melanoma Skin Cancer • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Current and emerging treatments for pediatric chronic hand eczema: A structured review (AAD 2026) - "Alitretinoin, methotrexate, and cyclosporine are used cautiously off-label. Dupilumab, approved for pediatric atopic dermatitis, has shown promising efficacy and safety in P-CHE trials... Effective P-CHE management requires a multifaceted approach that balances efficacy, safety, patient adherence, and family preference. The literature reflects a critical gap in P-CHE specific data, particularly amongst non-atopic subtypes and in the use of systemic therapies. Existing data is primarily derived from limited subgroup analyses within adult predominant trials, or from patients with atopic hand dermatitis enrolled within larger atopic dermatitis studies."

Clinical • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema. (PubMed, Dermatol Ther (Heidelb)) - "Delgocitinib and PUVA provided comparable short-term clinical efficacy in CHE, with a numerically greater DLQI reduction for delgocitinib. Proactive delgocitinib maintenance may help sustain disease control. Subtype-adapted treatment strategies could further optimize outcomes."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • CNS Disorders • Contact Dermatitis • Dermatology • Immunology • Pain • Pruritus • Sleep Disorder

Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema. (PubMed, J Drugs Dermatol) - "This consensus provides practical guidance supporting individualized, steroid-sparing CHE management while identifying areas for future research. &nbsp."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation • Pain • Pruritus

Vitamins and the Skin: Vitamin A and Retinoids in Dermatology. (PubMed, Clin Dermatol) - "Retinoids used as therapeutic agents include oral retinoids, e.g. isotretinoin, acitretin, alitretinoin, and bexarotene, and topical retinoids, e.g. isotretinoin, tretinoin, adapalene, tazarotene, and trifarotene. In addition, other retinoids, with distinct routes of administration (oral or topical), and distinct dosing or safety profiles, are recommended for different skin disorders. We discuss the mode of action and indications of retinoids used as pharmacologic agents in dermatology and provide an update on their use, effectiveness and tolerability."

Journal • Acne Vulgaris • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Lymphoma • Oncology • Psoriasis • Skin Cancer • Squamous Cell Carcinoma • T Cell Non-Hodgkin Lymphoma • Vitiligo

The Patient Journey: From Diagnosis to Therapeutic Management of Chronic Hand Eczema. (PubMed, Dermatitis) - "Topical corticosteroids remain the first-line treatment, whereas phototherapy and systemic options, including alitretinoin and immunosuppressants, are indicated in refractory cases. Recently, novel agents such as topical delgocitinib and biologics like dupilumab have expanded the therapeutic armamentarium, particularly for atopic CHE...Despite these advances, there is still a lack of standardized diagnostic tools, validated severity measures, and evidence-based treatment algorithms. Future efforts should focus on patient-centered, multidisciplinary care and further research to optimize disease control and quality of life in CHE."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Single-Cell Regulatory Network Analysis Identifies Adjunctive Drug Candidates in Early Risankizumab-Treated Psoriasis. (PubMed, Curr Pharm Des) - "These findings offer preliminary clues for future risankizumab-based combination strategies in psoriasis."

Journal • Dermatology • Immunology • Infectious Disease • Oncology • Psoriasis • CD4 • ELF3 • KLF5 • KLF9 • KRT14 • KRT6A • MAFB • NFIC • S100A8 • S100A9 • SREBF1

Retinoids enhance NK effector function against HIV-infected CD4 T cells. (PubMed, J Virol) - "From the retinoids tested, alitretinoin, tazarotene acid, and AM80 significantly enhanced NK natural cytotoxicity in the presence of IL-15. This makes the infected cells more vulnerable to being eliminated. Since some of these retinoids are already approved for medical use, they could offer a promising way to reduce persistent HIV reservoirs in the body and improve efforts to cure the infection."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL15

Hand eczema: comprehensive management and therapeutic perspectives in primary care (PubMed, Semergen) - "A focused history and clinical examination enable diagnostic orientation and allow the initiation, from the first consultation, of appropriate topical treatment, emollient use, and protection against triggering factors. Referral should be considered in severe, refractory cases or those with significant functional or occupational impact, in order to assess advanced therapies such as phototherapy, alitretinoin, dupilumab, oral JAK inhibitors, or topical delgocitinib."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

P015 Clinical characteristics of patients and treatment of moderate-to-severe chronic hand eczema in the UK: the RWEAL study. (PubMed, Br J Dermatol) - "Among 183 patients treated by dermatologists, 11% received alitretinoin, 10% phototherapy, 10% methotrexate, 8% ciclosporin and 7% dupilumab during the past 12-month period. This indicates a need for new treatment options that address the heterogeneous and multifactorial nature of CHE. The absence of clear lines of treatment after TCS suggests a need for UK-specific guidelines for CHE."

Journal • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We attempted to contribute to the existing CHE literature by producing comparative information on its treatments' relative efficacy; moreover, we found no published NMA study on available treatments for CHE before the conduct of our work. Our results can guide clinical decision-making."

Journal • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Cost-Effectiveness of Delgocitinib vs. PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream and psoralen with ultraviolet A (PUVA) light therapy are treatment options for patients with moderate or severe Chronic Hand Eczema (CHE) which has not adequately responded to treatment with topical corticosteroids...Efficacy and utility evidence for delgocitinib were derived from the DELTA 1, DELTA 2 clinical trials versus vehicle cream, and DELTA FORCE clinical trial versus alitretinoin... For treatment of patients with moderate-to-severe CHE which is inadequately treated by topical corticosteroids, delgocitinib cream provides both better clinical outcomes and lower costs for the healthcare payer in comparison with PUVA in the UK healthcare context."

Clinical • Cost effectiveness • HEOR • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream, alitretinoin, and psoralen with ultraviolet A (PUVA light therapy) are treatments used amongst patients with Chronic Hand Eczema (CHE) which has not adequately responded to topical corticosteroids alone. Due to limitations of available data, assumptions were required related to comparability of the IGA-CHE and PGA severity assessment tools, disease severity, treatments and outcome assessment timepoints, and the use of non-responder imputation. Notwithstanding these assumptions, amongst patients with moderate/severe CHE, treatment with delgocitinib cream is associated with both higher rates of treatment response and lower rates of discontinuation due to adverse events than either alitretinoin or PUVA light therapy."

Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema. (PubMed, J Drugs Dermatol) - "Comparative studies suggest delgocitinib offers superior or similar benefits to systemic therapies like the oral retinoid alitretinoin and the biologic dupilumab, with negligible systemic exposure. These findings support delgocitinib cream as an innovative and promising topical therapy addressing a critical unmet need in CHE patient management."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review. (PubMed, Dermatol Ther (Heidelb)) - "Despite being a first-line treatment, 40% of patients with CHE were inadequately treated with or contraindicated to TCS. Over one-quarter of patients progressed to phototherapy or systemic therapy. These results suggest a lack of effective and well-tolerated topical treatment options in CHE. Graphical Abstract available for this article."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Treatment of Refractory PRP with Off-label Guselkumab and Abrocitinib: A Promising Combination Therapy (EADV 2025) - "She had failed NBUVB phototherapy, cyclosporine, topical steroids and keratolytics, prednisone, and was currently taking acitretin alternating dose 25mg/35mg daily...She started combination of methotrexate and acitretin which failed. Ustekinumab 90mg every twelve weeks was initiated off-label with alitretinoin 30mg daily; no change... My case highlights that combination therapy of an IL-23 and JAK inhibitor are effective off-label in PRP. Current treatments approved for both psoriasis and atopic dermatitis seem to provide benefit, and combination therapy may be more beneficial. More research is necessary to find an effective single agent or to identify ideal doses of combination therapies."

Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Inflammation • Pruritus • Psoriasis • IL23A

Burden of Chronic Hand Eczema (CHE) in France Using the French Nationwide Claims Database (EADV 2025) - "Materials & Observational cohort study of CHE patients identified using the SNDS between 2017 and 2021, which included two groups: i) Alitretinoin CHE group: patients with at least one alitretinoin dispensing (first dispensing as index date); ii) Algorithm-based CHE group: patients identified using an algorithm combining sick leave in high-risk professions (medical sector; butchery, food industry and catering; print shop; hair and beauty care; traditional and industrial bakeries; construction/building; cleaning activity; maintenance and repair of motor vehicles), and concomitant dispensing of potent TCS, ciclosporin, topical tacrolimus, antihistamines, oral alitretinoin, or methotrexate (first sick leave as index date). This study highlights the CHE burden with a significant extra cost and impact on patients' professional activity and mental health. Moreover, these results demonstrate the need for alternatives to repeated, prolonged use of TCS in CHE and for..."

Claims database • Atopic Dermatitis • CNS Disorders • Contact Dermatitis • Depression • Dermatology • Immunology • Mood Disorders • Psychiatry • Sleep Disorder

Drug survival of systemic off-label therapies for treatment of hand eczema (EADV 2025) - "First- line treatment includes trigger avoidance, emollients, and topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI), and recently delgocitinib was approved as an additional topical treatment option. Alitretinoin is the only systemic treatment approved for HE, however a large proportion of patients receive off-label therapies when initiating systemic therapy...Off-label treatment included acitretin, azathioprine, cyclosporine, dupilumab, methotrexate and mycophenolate mofetil... Drug survival of traditional systemic therapies was comparable with cyclosporine showing slightly higher drug survival compared to acitretin, but comparable to most other systemic therapies. Dupilumab demonstrated the highest drug survival among off-label treatments, potentially reflecting higher efficacy and tolerability. This may indicate that most off-label treatment options in HE are inadequate in achieving disease control."

Asthma • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Respiratory Diseases

Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe Chronic Hand Eczema (EADV 2025) - P3 | "Current therapies, including topical corticosteroids, phototherapy (including psoralen ultraviolet A [PUVA]), and alitretinoin (approved for severe CHE in Europe, Canada, Israel and South Korea), may be hindered by side effects and poor patient adherence. The results of this MAIC analysis demonstrate that treatment with delgocitinib significantly improves both clinical and quality-of-life outcomes compared to PUVA plus as required TCS in severe CHE at week 12, including PGA/IGA-CHE, HECSI, and DLQI. These findings support delgocitinib as a highly efficacious and accessible alternative to PUVA ± TCS for managing severe CHE. As a topical treatment, delgocitinib also offers a more convenient alternative to PUVA based treatment, reducing the need for frequent clinic visits, alongside offering a favourable tolerability and safety profile."

Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Abrocitinib in combination with dupilumab for refractory atopic chronic hand eczema (EADV 2025) - "Treatment history included ultra-potent topical corticosteroids, topical calcineurin inhibitors, prednisone, methotrexate, cyclosporine, azathioprine and phototherapy...We recommended starting oral alitretinoin, but the patient could not afford it... The combination of biologic (dupilumab) and JAKi (abrocitinb) could be a favorable option for refractory severe atopic dermatitis, especially in cases with recalcitrant chronic hand eczema."

Combination therapy • Allergic Rhinitis • Asthma • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Pruritus • Respiratory Diseases • IL13 • IL22 • IL4

Safety of delgocitinib cream in adult patients with Chronic Hand Eczema (CHE): pooled analysis of five phase 2b and phase 3 trials (EADV 2025) - P2 | "Data encompass both the initial treatment period (ITP; delgocitinib cream twice daily [BID] vs cream vehicle BID or alitretinoin once daily for 12-16 weeks) and the subsequent as-needed treatment period (DELTA 3 and DELTA FORCE; delgocitinib cream 20 mg/g BID for up to 52 weeks of total treatment). The safety profile of delgocitinib cream during the as-needed treatment period remained consistent with the ITP, with AE rates decreasing in frequency over time. These pooled safety data support the robust safety profile of delgocitinib cream 20 mg/g for up to 52 weeks of treatment in adults with CHE."

Late-breaking abstract • P2b data • P3 data • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Infectious Disease

Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema. (PubMed, Drugs) - "Moreover, an active-controlled trial demonstrated that delgocitinib 20 mg/g cream had superior efficacy and apparent improved tolerability versus oral alitretinoin in adults with severe CHE. In summary, current data show that delgocitinib 20 mg/g cream is an efficacious and well tolerated treatment for moderate to severe CHE in adults. As the first topical treatment specifically approved for CHE, it presents a valuable new non-steroidal option in patients for whom topical corticosteroids are inadequate or inappropriate."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Treatment of Refractory PRP with Off-label Guselkumab and Abrocitinib: A Promising Combination Therapy (CDA 2025) - "She had failed NBUVB phototherapy, cyclosporine, topical steroids and keratolytics, prednisone, and was currently taking acitretin alternating dose 25mg/35mg daily...She started combination of methotrexate and acitretin which failed. Ustekinumab 90mg every twelve weeks was initiated off-label with alitretinoin 30mg daily; no change...Current treatments approved for both psoriasis and atopic dermatitis seem to provide benefit, and combination therapy may be more beneficial. More research is necessary to find an effective single agent or to identify ideal doses of combination therapies."

Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Pruritus • Psoriasis • IL23A

Screening for Potential Compounds Using Drug-Repurposing of N-Methyl-D-Aspartate (NMDA) Receptor for Autism Spectrum Disorder (ASD). (PubMed, Trop Life Sci Res) - "The drugs were alitretinoin, salicylic acid and indinavir, respectively. Finally, ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) predictions identify 4-androstenedione, tryptophan, carbocisteine and vitamin A as having minimal toxic effects. This study showed that alitretinoin, which was known to treat skin lesions from Kaposi's sarcoma, might have the ability to reverse the effect in ASD, particularly in NMDA receptors, potentially making a significant impact on the field of neurology and psychiatry."

Journal • Autism Spectrum Disorder • Genetic Disorders • Kaposi Sarcoma • Oncology • Psychiatry • Sarcoma • Solid Tumor • NRXN1